Fact Check: Misusing the Bayh-Dole Act’s March-In Rights is Not an Effective Way to Reduce Drug Prices
Claim: On December 7, the Biden administration proposed a policy framework claiming a newfound authority, under the 43-year-old Bayh-Dole Act, to rescind patent licenses on drugs, energy, climate change, and all other inventions that benefit from federal research funding based on the price of the resulting product. The administration asserts that this framework is an
New Op-Ed from C4IP Board: Europe Stands at a Crossroads on Technology Policy
Yesterday, the C4IP Board published an opinion piece in Euractiv highlighting how the European Commission’s recent proposal for standard-essential patents (SEPs) has empowered China to unilaterally set its own licensing terms, jeopardizing a longstanding model of international cooperation and threatening Europe’s own leadership in wireless technology. In the piece, the board explains how SEPs —
New Op-Ed from C4IP Board: Europe Stands at a Crossroads on Technology Policy Read More »
Celebrating American Innovation: Ashok Gadgil
C4IP is highlighting the accomplishments of Ashok Gadgil from the University of California, Berkeley. His groundbreaking invention, utilizing ultraviolet light to purify water, was brought to market pursuant to the Bayh-Dole Act and has since saved millions of lives across the globe. Ashok Gadgil was born in Mumbai, India, in 1950. He attended the University
Celebrating American Innovation: Ashok Gadgil Read More »
New Op-Ed from C4IP Co-Chairs David Kappos and Andrei Iancu: President Biden’s domestic technology seizure plan
Over the weekend, C4IP Co-Chairs and former USPTO Directors David Kappos and Andrei Iancu published an opinion piece in The Hill detailing how the Biden administration’s new proposal for march-in rights under the Bayh-Dole Act would decimate innovation across numerous crucial technology sectors. The administration’s unprecedented proposal, announced in December, would allow government bureaucrats to
New Op-Ed from Institute for Policy Innovation Resident Scholar Merrill Matthews: Blame Washington for Drug Shortages
Merrill Matthews, a resident scholar with the Institute for Policy Innovation, recently published an opinion piece in RealClearHealth calling attention to the numerous attacks on intellectual property that are exacerbating ongoing shortages of prescription medicines. More than 300 drugs are currently in shortage, including 15 cancer drugs, due to falling profit margins in the drug